阿立哌唑与利培酮治疗女性精神分裂症对照观察

Controlled observation of Aripiprazole and Risperidone in the treatment of female schizophrenia

目的:探讨阿立哌唑治疗女性精神分裂症的临床疗效及安全性。方法:将128例女性精神分裂症患者随机分成两组各64例。阿立哌唑组口服阿立哌唑,利培酮组口服利培酮;观察8周。于治疗前及治疗第2周、4周、8周末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果:治疗8周末,阿立哌唑组显效率75.00%,有效率93.75%;利培酮组分别为68.75%、90.63%。两组比较差异均无显著性(χ2=0.59,0.32;P>0.05);两组不良反应均轻微,但阿立哌唑组锥体外系反应、泌乳和闭经等不良反应发生率低于利培酮组。结论:阿立哌唑治疗女性精神分裂症患者疗效显著,与利培酮疗效相当,且安全性高。

Objective：To explore the clinical efficacy and safety of Afipiprazole and Risperidone in the treatment of female schizophrenia. Methods： 134 female patients with schizophrenia were randomly divided into two groups, each group of 67 cases. The Aripiprazole group oral Aripiprazole, Risperidone group oral Risperidone;observation of 8 weeks. In the before treatment and treatment of 2, 4, 8 weekend using the Positive in Negative Syn- drome Scale to evaluate the efficacy, side effects rating scale adverse reactions. Results：In the treatment of 8 weekend, Aripiprazole group markedly eftec- tive rate of 75.00% ,efficiency of 93.75% ;the Risperidone group were 68.75% ,90.63%. The difference between the two groups were not significant（ χ2 = 0.59,0.32 ;P 〉 0.05 ）. Two groups of adverse reactions were mild, but the Aripiprazole group of extrapyramidal system reaction, the body weight in- crease,the incidence of adverse reactions such as lactation and amenorrhea is lower than the Risperidone group. Conclusion： Aripiprazole have significant effect and high safety for treatment of female patients.